Johnson & Johnson to acquire eye‑disease biotech Ollin Biosciences for up to $3.3 billion

Johnson & Johnson announced on 16 Nov 2026 that it will buy Texas‑based Ollin Biosciences. The deal includes a $2.2 billion cash upfront payment and milestone payments that could bring total consideration to roughly $3.3 billion. Ollin’s lead candidate, the bispecific antibody OLN324, is in Phase III trials for wet age‑related macular degeneration and diabetic macular oedema. The transaction is expected to close before the end of 2026, subject to regulatory approval.

The acquisition expands J&J’s ophthalmology pipeline and adds a late‑stage asset that could diversify revenue beyond its existing anti‑VEGF drugs. The deal’s size, confirmed at up to $3.3 billion, may affect J&J’s cash balance and could influence analyst earnings forecasts for the coming year.

  • Total headline value differs between $3.4 billion (early reports) and $3.3 billion (company‑disclosed terms)
  • Milestone amount reported as $1.2 billion in some early articles versus $1.125 billion in the confirmed terms

Sources